Renal Ex Vivo SYN002 Perfusion to Eliminate CMV Transmission

Donor organs often carry latent Cytomegalovirus (CMV) infection that may be transmitted to the recipient. The goal of this clinical trial is to determine the safety of SYN002 treatment during Ex-Vivo Organ Perfusion (EVOP) in clinical kidney transplantation. Donor kidneys will be treated on the EVOP system with SYN002 in order to decrease the burden of latent CMV in the organ and mitigate the transmission of cytomegalovirus (CMV).

NCT Number	NCT07488481
Lead Sponsor	University Health Network, Toronto
Conditions	Cytomegalovirus (CMV) Infection, Kidney Transplant Recipient
Enrollment	12 participants
Start Date	2026-03-16
Primary Completion	2027-03-16 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-23